Eli Lilly and Company $LLY Stock Sold by Greenleaf Trust

Key Points

• Greenleaf Trust reduced its Eli Lilly position by 6.3% in the third quarter, selling 1,337 shares and retaining 19,776 shares valued at approximately $22.9 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with revenue rising 38.6% year over year to $24.4 billion and EPS of $7.48, exceeding analyst expectations. Demand for Mounjaro and Zepbound helped support a higher full-year outlook.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and several firms raising price targets, although the stock’s premium valuation and reliance on GLP-1 drugs leave it exposed to pricing pressure and potentially slower growth.

Greenleaf Trust lowered its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,776 shares of the company's stock after selling 1,337 shares during the quarter. Greenleaf Trust's holdings in Eli Lilly and Company were worth $22,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Marshall & Sterling Wealth Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after purchasing an additional 15 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at about $42,000. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $49,000. Caitlin John LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at about $64,000. Finally, IMG Wealth Management Inc. grew its position in Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock worth $72,000 after acquiring an additional 50 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,412.06 on Tuesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,449.68. The firm has a market cap of $1.33 trillion, a P/E ratio of 45.83, a P/E/G ratio of 1.73 and a beta of 0.46. The business's 50 day moving average price is $1,200.81 and its 200-day moving average price is $1,094.25.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the company earned $7.02 earnings per share. The firm's revenue for the quarter was up 38.6% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's payout ratio is currently 22.46%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last 90 days. 0.14% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research note on Monday. Bank of America reissued a "buy" rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Weiss Ratings downgraded shares of Eli Lilly and Company from a "buy (b+)" rating to a "buy (b)" rating in a research note on Friday. Citigroup upped their price target on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a "buy" rating in a report on Friday. Finally, Morgan Stanley raised their price target on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an "overweight" rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.